ArticleJapanese journal of radiology2026
MRI-defined parametrial venous invasion in locally advanced cervical cancer: association with pathological venous invasion, pretreatment lymph node metastasis, and survival outcomes.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate MRI-defined parametrial venous invasion (mrPMVI) for detecting pathological parametrial venous invasion (pPMVI) and its associations with pretreatment lymph node metastasis (LNM) and survival outcomes in locally advanced cervical cancer. MATERIALS AND
methodsThis retrospective study included 42 patients with cervical cancer with parametrial invasion on MRI or histopathology, corresponding to International Federation of Gynecology and Obstetrics 2018 stage IIB or higher disease. Fifteen patients underwent surgery without preoperative therapy and were included in the pathological validation analysis. Image interpretation was primarily based on T2-weighted and diffusion-weighted imaging. Two radiologists independently assessed mrPMVI using a five-point scoring system. Scores ≥ 3 were predefined as mrPMVI-positive. Diagnostic performance for pPMVI and interobserver agreement were evaluated. Univariable logistic and Cox regression analyses were performed for pretreatment LNM and survival outcomes, respectively.
resultspPMVI was present in 10 of 15 patients. The five-point mrPMVI score showed an area under the receiver operating characteristic curve of 0.87 (95% confidence interval [CI], 0.60-0.98) for detecting pPMVI. The predefined threshold (≥ 3) yielded 30.0% sensitivity and 100% specificity. Interobserver agreement for the five-point mrPMVI score was substantial (linearly weighted κ = 0.75). mrPMVI positivity was associated with pretreatment LNM (odds ratio = 4.00, 95% CI: 1.05-15.26, p = 0.042). During a median follow-up of 24.0 months, 16 patients experienced disease progression and 10 died. mrPMVI positivity was associated with shorter progression-free survival (hazard ratio = 34.25, 95% CI: 4.35-269.91; p < 0.001) and overall survival (hazard ratio = 10.16; 95% CI: 1.28-80.61, p = 0.028).
conclusionThe mrPMVI score showed potential for identifying pPMVI, although the predefined threshold was highly specific but insensitive. mrPMVI positivity was associated with pretreatment LNM and survival outcomes, suggesting potential complementary value for risk characterization in locally advanced cervical cancer.
Indexed as
Identifiers
42888363What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.